JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cross, J. V.
Right arrow Articles by Templeton, D. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cross, J. V.
Right arrow Articles by Templeton, D. J.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

J Biol Chem, Vol. 274, Issue 44, 31150-31154, October 29, 1999


Quinone Reductase Inhibitors Block SAPK/JNK and NFkappa B Pathways and Potentiate Apoptosis*

Janet V. CrossDagger , Joseph C. DeakDagger , Elizabeth A. RichDagger §, Yongyi Qian, Margaret Lewis, Louis A. Parrott, Keiko Mochida§, Daniel Gustafsonparallel , Scott Vande Pol, and Dennis J. Templeton**

From the § Department of Medicine, Institute of Pathology, Case Western Reserve University, Cleveland, Ohio 44106 and parallel  Department of Environmental Health, Center for Environmental Toxicology and Technology, Colorado State University, Fort Collins, Colorado 80523

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

A variety of environmental stresses stimulate the mitogen-activated protein kinase/extracellular signal-regulated kinase (ERK) kinase (MEKK) > stress-activated protein kinase (SAPK)-ERK kinase (SEK) > SAPK/c-Jun NH2-terminal kinase (JNK) stress-activated protein kinase cascade and coordinately activate the transcription factor NFkappa B. Mechanisms of stress activation upstream of MEKK1 have not been precisely determined. Redox mechanisms involving sulfhydryls are likely because N-acetyl-cysteine at millimolar concentrations blocks stress signals. Because intracellular sulfhydryl concentrations can be regulated through redox cycling involving reactive quinones (1), we tested the ability of quinone reductase inhibitors to alter stress signaling. Several quinone reductases are inhibited by dicoumarol, a coumarin derivative. Dicoumarol prevented SAPK activation in vivo by chemical cell stressors and also prevented SAPK activation induced by expression of the tumor necrosis factor alpha  (TNFalpha ) receptor-associated protein TRAF2 but not by expression of truncated active MEKK1. Other coumarin derivatives failed to block SAPK activation, but other inhibitors of quinone reductases, particularly menadione, similarly blocked SAPK activation. Cells deficient in a major quinone reductase, NQO1, displayed hypersensitivity to dicoumarol stress inhibition, whereas SAPK in cells reconstituted with the NQO1 gene displayed relative dicoumarol resistance. Consistent with the proposed role of overlapping upstream signaling cascades in activation of NFkappa B, dicoumarol also blocked NFkappa B activation in primary macrophages stimulated with either lipopolysaccharide or TNFalpha . In addition, dicoumarol strongly potentiated TNFalpha -induced apoptosis in HeLa cells, probably by blocking the anti-apoptotic effect of NFkappa B. The ability of dicoumarol to simultaneously inhibit SAPK and NFkappa B activation and to potentiate apoptotic cell death suggests that SAPK is not an obligate participant in apoptosis. Dicoumarol, currently in clinical use as an oral anticoagulant, represents a potential therapeutic inhibitor of the SAPK and NFkappa B response.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

The MEKK1 protein kinase (2) is a proximate activator of the stress-activated protein kinase (SAPK,1 alternatively known as JNK) stress-signaling pathway (3). A variety of environmental stresses, including inflammatory cytokines, hyperosmotic shock, and UV light, stimulate the cascade (4). MEKK1 is implicated in apoptotic cell death (5, 6), but perhaps surprisingly MEKK1 activates NFkappa B pathways (7, 8) that induce expression of genes to counteract the apoptotic death response (9-11).

Stress activators upstream of MEKK1 remain obscure. The small G-proteins Rac and Rho activate stress signaling (12, 13), but their placement in relation to MEKK1 is unclear. TNFalpha and the TNFalpha receptor-associated effector protein TRAF2 activate the SAPK pathway (14, 15). Reactive oxygen species are implicated in activation of stress kinase pathways in response to TNFalpha and UV irradiation. Reducing agents such as N-acetyl-cysteine at millimolar concentrations can block stress signals (15), suggesting that redox mechanisms are required for an undefined and probably early event in transmission of stress signals.

Intracellular thiols can be consumed by a process termed "redox cycling" in which reactive quinones catalyze the oxidation of sulfhydryls to disulfides. In the cell, reactive quinones are regulated by the enzymatic activity NAD(P)H dehydrogenase (formerly DT-diaphorase) (E.C. 1.6.99.2) (16), representing a family of cytoplasmic flavo-enzymes responsible for two-electron reduction of quinones (17), using NADPH or NADH as electron donor. NAD(P)H dehydrogenase, also termed "quinone reductase," is inhibited by dicoumarol, a coumarin derivative (18). Like other coumarins, dicoumarol is used clinically to inhibit blood coagulation processes dependent on vitamin K, a biological quinone.

Here we report evidence that inhibitors of quinone reductases can inhibit SAPK and NFkappa B signaling. In addition, dicoumarol potentiates the apoptotic effect of TNFalpha , probably by preventing anti-apoptotic events dependent upon NFkappa B.

    MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

SAPK Activation Assays-- Human embryonic kidney 293 cells, or other cells as indicated, were seeded at 105 cells/35-mm plastic dish and transferred to serum-free medium 18 h before stimulation as indicated in the figure legends. 20 min following stimulation with 400 mM sorbitol (or as indicated) cells were assayed for SAPK/JNK activity as described (3) using rabbit anti-holo-SAPK-beta 1 (p54) antiserum and glutathione S-transferase-Jun (5-79) as substrate. Anti-MAPK C-terminal peptide polyclonal serum was obtained from Michael Dunn (Milwaukee, WI). Following gel electrophoresis, proteins were transferred to polyvinylidene difluoride membrane and labeled proteins detected and quantified using a Packard Instant Imager.

Plasmid Transfections-- Plasmid encoding the catalytic fragment of MEKK under a CMV promoter have been described (3); these were transfected into recipient cells using calcium phosphate. The SAPK-beta 1 (p54) allele expressed as a glutathione S-transferase fusion protein using the pEBG vector was obtained from James Woodgett (Toronto, Ontario).

NFkappa B Assays-- Human pulmonary alveolar macrophages were isolated by bronchoalveolar lavage of healthy adults. Nuclear extracts were prepared either immediately upon isolation or after 30 min of incubation in medium with or without LPS or TNFalpha . DNA binding of NFkappa B in nuclear extracts was determined using the radiolabeled oligonucleotide 5'-CTAGTAGCGGAAAGTCCCTTG-3'. Polyclonal antisera detecting p65 and p50 amino termini was a gift from Nancy Rice, NCI, Frederick, MD.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

To determine whether quinone reductase inhibitors affect transmission of stress signals, we pretreated cultures of human embryonic kidney 293 cells with dicoumarol before stimulation with hyperosmotic sorbitol or anisomycin. Dicoumarol alone did not affect SAPK but completely blocked activation by osmotic shock and anisomycin in 293 cells (Fig. 1A) and in Jurkat and resting peripheral T lymphocytes (data not shown and see below). Dicoumarol also blocked SAPK activation by UV irradiation and ceramide induced by treatment with sphingomyelinase (Fig. 1B). Warfarin and coumarin, agents that inhibit the vitamin K cycle like dicoumarol, did not inhibit SAPK activation (see Table I), suggesting that vitamin K metabolism is unrelated to stress signaling.


View larger version (25K):
[in this window]
[in a new window]
 
Fig. 1.   Inhibition of SAPK activation by dicoumarol. 293 cells were preincubated with 300 µM dicoumarol followed by stimulation with hypertonic sorbitol (400 mM, lanes 3 and 4), anisomycin (10 µg/ml, lanes 5 and 6), sphingomyelinase (from Bacillus cereus, 10 units/ml, lanes 8 and 9) or UV light (254 nM, 20 J/m2, lanes 10 and 11) for 20 min. Cells were lysed and SAPK assayed by in vitro kinase assay. All of these treatments resulted in strong stimulation of SAPK activity, which was prevented by the 10 min pre-incubation with 300 µM dicoumarol.

                              
View this table:
[in this window]
[in a new window]
 
Table I
Inhibition of SAPK by respiratory and redox-active chemicals
Assay of hyperosmotic sorbitol stimulated SAPK in 293 cells treated with the indicated inhibitors. Except as noted, inhibitor pretreatment preceded stimulation with sorbitol by 10 min and were assayed for SAPK activity as described above 20 min following stimulation. Agents are grouped together under broad categories but typically have several known inhibitory roles. Inhibitory agents were compared with controls treated with the appropriate solvent. Averages and standard deviations were derived from assays in separate experiments.

Inhibition of SAPK activation by dicoumarol was dose-dependent (Fig. 2), with an IC50 between 19 and 38 µM in 293 cells. Dicoumarol blocked SAPK activation in response to expression of TRAF2, a TNFalpha receptor interacting protein that activates SAPK (15) (Fig. 3A). In contrast, dicoumarol was unable to block SAPK activation in response to expression of truncated active MEKK1, indicating that the point of dicoumarol inhibition of SAPK activation lies downstream of TRAF2 but upstream of MEKK1 in a poorly characterized segment of the stress-signaling cascade.


View larger version (13K):
[in this window]
[in a new window]
 
Fig. 2.   Concentration dependence of dicoumarol inhibition of SAPK. 293 cells were treated with serial dilutions of dicoumarol, and stimulated with sorbitol as described in Fig. 1. The IC50 of dicoumarol for SAPK inhibition is approximately 19-33 µM.


View larger version (25K):
[in this window]
[in a new window]
 
Fig. 3.   A, dicoumarol blocks SAPK activation at a point upstream of MEKK1 and downstream of TRAF2. 293 cells were transfected with empty pCMV plasmid (lanes 1 and 2), TRAF2-CMV (lanes 3 and 4) or Delta MEKK-EE-CMV plasmid (lanes 5 and 6). Endogenous SAPK was assayed by immunoprecipitation and in vitro kinase assay. Dicoumarol reduced basal SAPK activity and TRAF2-stimulated activity but did not block SAPK activation in MEKK1 transfected cells. B, dicoumarol does not inhibit activation of SAPK by heat shock. Cells were stimulated with sorbitol or anisomycin as above or by incubating at 45 °C for 45 min (heat shock) The heat shock results represent a longer exposure of the same gel, because stimulation of SAPK by heat shock is comparatively weaker than the other stimuli. Dicoumarol failed to inhibit activation of SAPK by heat shock. C, dicoumarol does not block TPA activation of MAPK. HeLa cells (used because TPA poorly stimulated MAPK in 293 cells) were treated with 400 mM sorbitol (lanes 3 and 4) or with 1 µg/ml TPA (lanes 5 and 6) for 20 min. Extracts were divided and assayed for SAPK activation (top) and MAPK activation using immune complex kinase assays and the indicated substrates. Dicoumarol reduced activation of both SAPK and MAPK by hypertonic sorbitol treatment (lane 4) but did not block stimulation of MAPK by TPA (lane 5).

In contrast to its ability to inhibit activation of SAPK by agents such as sorbitol and anisomycin, dicoumarol failed to inhibit activation of SAPK in response to heat shock (Fig. 3B), which is believed to proceed by an alternate pathway (19). The specificity of dicoumarol inhibition for stress signaling was demonstrated by its failure to inhibit activation of MAPK in CV1 cells in response to TPA (Fig. 3C). However dicoumarol did block MAPK activation resulting from osmotic shock, which likely proceeds via upstream pathways that overlap the SAPK signaling pathway, including the involvement of MEKK1 (20). Thus, dicoumarol inhibition is specific for stress-activated pathways and does not affect mitogenic signaling.

To verify the importance of quinone reductases in stress signaling, we tested a subline of CHO fibroblasts (clone 77254) deficient in NQO1, one of the major cellular quinone reductases (21). Although these cells are still capable of activating SAPK in response to hyperosmotic sorbitol, they have a reduced IC50 for dicoumarol inhibition of SAPK activation, about 5 µM (Fig. 4A). Reconstitution of NQO1 by stable expression of the NQO1 gene (21) reduced the sensitivity of these cells to dicoumarol (Fig. 4B). Thus, inhibition of SAPK activation by dicoumarol can be partly abrogated by expression of NQO1, genetically supporting a role for NQO1 and other quinone reductases in stress signaling.


View larger version (15K):
[in this window]
[in a new window]
 
Fig. 4.   Expression of the NQO1 gene reduces sensitivity to SAPK inhibition by dicoumarol. A, an NQO1-deficient subline of CHO cells is hypersensitive to dicoumarol inhibition of SAPK relative to 293 cells. Cultures received a 10-min pretreatment with varying concentrations of dicoumarol before 400 mM sorbitol treatment. SAPK was assayed as in Fig. 1. B, CHO-77254 cells stably transfected with a plasmid encoding NQO1 regained resistance to higher levels of dicoumarol, assayed as in A. The IC50 of CHO-77254 was below 5 µM, whereas in the reconstituted cells the IC50 was between 10 and 20 µM.

We tested whether other metabolic toxins and redox inhibitors might be able to inhibit SAPK activation (Table I). No inhibition of SAPK activation was seen with coumarin or warfarin anticoagulants, inhibitors of mitochondrial oxidative phosphorylation, or extracellular superoxide dismutase or catalase, which reduce intracellular levels of superoxide and hydrogen peroxide, respectively. The vitamin K-related quinone menadione blocked SAPK activation with an IC50 approximately the same as dicoumarol. Notably, menadione is an in vitro substrate of quinone reductases, and competitively inhibits these enzymes in vivo. Two other quinone-related compounds, hydroquinone and butylated hydroxyanisole, inhibited SAPK at lower efficiency, requiring very high concentrations to see a significant inhibition. Thus dicoumarol and menadione, followed by other quinones, were most effective at blocking SAPK activation. These inhibitor studies suggest a role for quinone reduction, rather than events such as oxidative phosphorylation, in stress signaling.

These data suggest that dicoumarol inhibition of SAPK signaling may be related to a change in the state of quinone reduction in the cell. Specifically, inhibition of quinone reductases by dicoumarol would result in a decrease in the levels of reduced quinones in the cell. We examined whether replacing the reduced quinones would restore the ability of the cells to signal to SAPK (Fig. 5). Although dicoumarol completely inhibited activation of SAPK in response to sorbitol (lane 4), the addition of increasing amounts of hydroquinone restored the SAPK activation in a dose-responsive manner (lanes 5-8). Treating the cells with hydroquinone alone had no effect on SAPK activity (lanes 9-12). These data suggest that the inhibition of SAPK activation by dicoumarol is due in large part to the decrease in reduced quinones that results from the inhibition of quinone reductases, supporting a role for quinone reduction in establishing an intracellular environment that is permissive for stress signaling.


View larger version (18K):
[in this window]
[in a new window]
 
Fig. 5.   Addition of hydroquinone overcomes dicoumarol inhibition of SAPK activation. CV-1 cells were pretreated for 10 min with dicoumarol and hydroquinone at the indicated concentrations, and then stimulated with 400 mM sorbitol for 20 min. SAPK activity was measured as in Fig. 1. Addition of hydroquinone restored SAPK activation in the presence of dicoumarol.

We examined consequences of interfering with stress signaling using dicoumarol. Many stress stimuli, for example TNFalpha and LPS, activate both SAPK and the NFkappa B transcription factor. Recent findings have suggested that the upstream pathways leading to NFkappa B activation may significantly overlap with those for SAPK activation, including a role for MEKK1 in both signaling cascades (7, 8). Dicoumarol blocked NFkappa B activation, indicated by the loss of NFkappa B-DNA binding activity induced by LPS or TNFalpha in human pulmonary alveolar macrophages (Fig. 6A).


View larger version (30K):
[in this window]
[in a new window]
 
Fig. 6.   A, dicoumarol inhibits activation of NFkappa B by TNFalpha or LPS. Primary human pulmonary macrophages were tested immediately upon isolation (lane 1) or after culture for 30 min (lanes 2-9). Mobility shifted complexes appeared following stimulation with LPS (1 µg/ml) (lane 3) or TNFalpha (30 ng/ml) (lane 7). The shifted complexes were inhibited by pre-incubation with dicoumarol (lanes 4 and 8). Participation of p50 and p65 NFkappa B proteins in the shifted complexes was demonstrated in LPS-stimulated extracts using anti-p50 and anti-p65 polyclonal antibodies (lanes 5 and 6). A 30-fold excess of unlabeled oligonucleotide competitor blocked specific complexes (lane 9). B, dicoumarol synergizes with TNFalpha to induce apoptosis. HeLa cells were pretreated with 25 µM dicoumarol followed by 30 ng/ml TNFalpha for 8 h or individually as indicated. Cells were fixed with methanol, stained with propidium iodide, and assayed using flow cytometry for DNA content. The ordinate shows cell number normalized to the mode, the abscissa relative fluorescence. Apoptotic cells with lower than 2N DNA content were enumerated, as indicated near each panel. Dicoumarol increased the fraction of apoptotic cells in synergy with TNFalpha , as did the protein synthesis inhibitor cycloheximide (CHX).


View larger version (37K):
[in this window]
[in a new window]
 
Fig. 7.   Model for regulation of SAPK and NFkappa B activation by dicoumarol. Cytokine and physical stresses simultaneously activate apoptotic and survival pathways, resulting in variable cell response (death or survival) depending on context-specific variables. Proximal events in the "survival" pathway depend upon a regulated redox environment for an uncharacterized event distal to the function of TRAF2 but proximal to MEKK1. This event is regulated by disulfides (15) and is also targeted by dicoumarol. The well established role of dicoumarol in inhibiting quinone reductases as well as the role of quinones in disulfide regulation via redox cycling suggest an important role for quinone reductases in maintaining the overall redox environment critical for transmission of stress signals. The "survival" pathway almost certainly involves new gene expression controlled by NFkappa B. The simultaneous inhibition of NFkappa B and SAPK activation pathways together with synergism with TNFalpha to produce apoptosis demonstrates that SAPK activation is not obligately required for apoptosis.

NFkappa B activation inhibits TNFalpha induced apoptosis (9-11). Disruption of TNFalpha -induced gene expression by cycloheximide or actinomycin D synergizes with TNFalpha -induced apoptosis. Like cycloheximide, dicoumarol also potentiated apoptosis of HeLa cells treated with TNFalpha (Fig. 6B). This synergism is likely a result of the inhibition of NFkappa B activation by dicoumarol and points to possible therapeutic uses for dicoumarol in synergism with this or other apoptosis-inducing agents. Importantly, the simultaneous inhibition of SAPK/JNK activation and potentiation of apoptosis demonstrates that SAPK/JNK activation is not a required event in the apoptotic response.

Peripheral blood lymphocytes undergo DNA synthesis in response to the mitogen PHA. Pretreatment of human peripheral blood lymphocytes with hypertonic NaCl stimulated SAPK and blocked DNA synthesis in response to PHA (Table II). Pretreatment of peripheral blood lymphocytes with dicoumarol before hypertonic shock prevented SAPK activation and restored PHA-stimulated DNA synthesis. Thus, inhibition of PHA-induced cell cycle entry in response to hypertonic shock is a specific stress-induced effect rather than a nonspecific toxic effect. In future experiments, dicoumarol should similarly be useful for identifying other biologic consequences of stress signaling.

                              
View this table:
[in this window]
[in a new window]
 
Table II
Dicoumarol reverses osmotic shock blockade of PHA activation of peripheral blood mononuclear cells
Resting peripheral blood mononuclear cells were pre-treated either with hypertonic saline (100 mM NaCl) for 30 min or with 300 µM dicoumarol for 10 min followed by 30 min in hypertonic saline. Lymphocytes were washed to remove stimulators and replaced in medium containing PHA. DNA synthesis during a period 24-48 h following PHA exposure was monitored by incorporation of 3H-thymidine, and the results of triplicate samples are shown. SAPK activity was assayed as in Fig. 1. Dicoumarol blocks both the osmotic shock activation of SAPK and prevents the reduction of PHA activation observed following osmotic shock. Similar results were observed in two other experiments.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Our data demonstrate an obligate role for a dicoumarol-inhibitable activity in stress signaling at a point upstream of MEKK1, and downstream of osmotic shock, LPS, anisomycin, TNFalpha , and the TNFalpha receptor-associated protein TRAF2 (Fig. 7). In contrast, this dicoumarol sensitive activity appears dispensable for activation of SAPK by heat shock, which is thought to proceed via a distinct pathway. Our data supports the hypothesis that heat shock acts via an alternate pathway which does not share the apparent dependence on quinone reductase function.

Quinone reductases likely provide an intracellular environment permissive to stress signaling rather than themselves being activated during the signaling. Inhibition of these quinone reductases by dicoumarol would interfere with this environment, and inhibit the ability of the cells to transmit stress signals. In support of this, replacing reduced quinones that are lost as a result of dicoumarol inhibition of quinone reductases restores the ability of the cells to signal to SAPK. These data suggest a role for quinone reduction in generating this permissive intracellular environment. Interestingly, very high concentrations of hydroquinone inhibit activation of SAPK in response to sorbitol, suggesting that there is a tightly regulated balance, where either too high or low levels of reduced quinones are detrimental to stress signal transmission.

Cells lacking NQO1 display increased sensitivity to dicoumarol treatment. The observation that these cells continue to signal to SAPK supports our model in which NQO1 is involved in establishing an intracellular environment permissive for stress signaling, rather than fulfilling an obligate role in a linear pathway. In the absence of NQO1, other less abundant dicoumarol-sensitive quinone reductases assume responsibility for establishing the homeostatic quinone balance. When these NQO1 deficient cells are treated with dicoumarol, this balance is more easily upset, as reflected in the decreased IC50 for SAPK signaling when compared with the cells that have been reconstituted by stable transfection of NQO1.

Inhibition of stress signaling by dicoumarol synergizes with TNF-alpha to promote apoptosis, suggesting a role for quinone reductases in the regulation of apoptotic events. Other evidence similarly supports this theory. First, using the SAGE technique, it was shown that expression of the apoptotic regulator p53 strongly activated expression of a quinone reductase among several other redox enzymes (22). In a separate study, induction of the p53-induced cell cycle inhibitor p21/cip1/waf1 by aziridinylbenzoquinones was also inhibited by dicoumarol (23), demonstrating a requirement for quinone reductases in this induction.

NFkappa B is a central participant in pathologic inflammation (24). SAPK is also activated in pathologic inflammation, and in other pathologies such as hepatic regeneration and cirrhosis (25), and in reperfusion following cardiac and cerebral vascular occlusion (26). Dicoumarol or similar quinone reductase inhibitors might serve clinically to inhibit stress and inflammatory processes. Dicoumarol has been used as an oral anticoagulant in patients for many years. Although it is a poison, the known toxic effects of its administration in animals are related solely to anticoagulation, which can be reversed by simultaneous administration of vitamin K. Inhibition of SAPK and NFkappa B by dicoumarol or related compounds might thus prove doubly valuable; first for identifying the function of stress signals in experimental situations, and also for translation into therapeutic utility in the clinical setting.

    ACKNOWLEDGEMENTS

We thank R. Michael Sramkoski for assistance with flow cytometry at the Case Western Reserve University Cancer Center Core Facility, and Minhong Yan, Tim Shannon, and Edwina Lerner for helpful discussions.

    FOOTNOTES

* This work was supported by National Institutes of Health Grants CA-66134 and ES/HL-09249-01 and awards from the American Cancer Society and the Council for Tobacco Research.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger These authors contributed equally to this work.

Supported by National Institutes of Health Grants HL-57940 and M01-RR-00080.

** To whom correspondence should be addressed. Tel.: 216-368-1266; Fax: 216-368-1300; E-mail: djt2@po.cwru.edu.

    ABBREVIATIONS

The abbreviations used are: SAPK, stress-activated protein kinase; JNK, c-Jun NH2-terminal kinase; MAPK, mitogen-activated protein kinase; MEKK, MAPK/extracellular signal-regulated kinase kinase; CMV, cytomegalovirus; LPS, lipopolysaccharide; TPA, 12-O-tetradecanoylphorbol-13-acetate; CHO, Chinese hamster ovary; PHA, phytohemagglutinim.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

1. Brunmark, A., and Cadenas, E. (1989) Free Radic. Biol. Med. 7, 435-477[CrossRef][Medline] [Order article via Infotrieve]
2. Lange-Carter, C. A., Pleiman, C. M., Gardner, A. M., Blumer, K. J., and Johnson, G. L. (1993) Science 260, 315-319[Abstract/Free Full Text]
3. Yan, M., Dai, T., Deak, J. C., Kyriakis, J. M., Zon, L. I., Woodgett, J. R., and Templeton, D. J. (1994) Nature 372, 798-800[Medline] [Order article via Infotrieve]
4. Kyriakis, J. M., and Avruch, J. (1996) J. Biol. Chem. 271, 24313-24316[Free Full Text]
5. Cardone, M. H., Salvesen, G. S., Widmann, C., Johnson, G., and Frisch, S. M. (1997) Cell 90, 315-323[CrossRef][Medline] [Order article via Infotrieve]
6. Deak, J. C., Cross, J. V., Lewis, M., Qian, Y., Parrott, L. A., Distelhorst, C. W., and Templeton, D. J. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 5595-5600[Abstract/Free Full Text]
7. Meyer, C. F., Wang, X., Chang, C., Templeton, D., and Tan, T. H. (1996) J. Biol. Chem. 271, 8971-8976[Abstract/Free Full Text]
8. Lee, F. S., Hagler, J., Chen, Z. J., and Maniatis, T. (1997) Cell 88, 213-222[CrossRef][Medline] [Order article via Infotrieve]
9. Beg, A. A., and Baltimore, D. (1996) Science 274, 782-784[Abstract/Free Full Text]
10. Wang, C. Y., Mayo, M. W., and Baldwin, A., Jr. (1996) Science 274, 784-787[Abstract/Free Full Text]
11. Van Antwerp, D. J., Martin, S. J., Kafri, T., Green, D. R., and Verma, I. M. (1996) Science 274, 787-789[Abstract/Free Full Text]
12. Minden, A., Lin, A., Claret, F. X., Abo, A., and Karin, M. (1995) Cell 81, 1147-1157[CrossRef][Medline] [Order article via Infotrieve]
13. Coso, O. A., Teramoto, H., Simonds, W. F., and Gutkind, J. S. (1996) J. Biol. Chem. 271, 3963-3966[Abstract/Free Full Text]
14. Liu, Z. G., Hsu, H., Goeddel, D. V., and Karin, M. (1996) Cell 87, 565-576[CrossRef][Medline] [Order article via Infotrieve]
15. Natoli, G., Costanzo, A., Ianni, A., Templeton, D., Woodgett, J., Balsano, C., and Levrero, M. (1997) Science 275, 200-203[Abstract/Free Full Text]
16. Lind, C., Cadenas, E., Hochstein, P., and Ernster, L. (1990) Methods Enzymol. 186, 287-301[Medline] [Order article via Infotrieve]
17. Jaiswal, A. K., Burnett, P., Adesnik, M., and McBride, O. W. (1990) Biochemistry 29, 1899-1906[CrossRef][Medline] [Order article via Infotrieve]
18. Hosoda, S., Nakamura, W., and Hayashi, K. (1974) J. Biol. Chem. 249, 6416-6423[Abstract/Free Full Text]
19. Adler, V., Schaffer, A., Kim, J., Dolan, L., and Ronai, Z. (1995) J. Biol. Chem. 270, 26071-26077[Abstract/Free Full Text]
20. Yujiri, T., Sather, S., Fanger, G. R., and Johnson, G. L. (1998) Science 282, 1911-1914[Abstract/Free Full Text]
21. Gustafson, D. L., Beall, H. D., Bolton, E. M., Ross, D., and Waldren, C. A. (1996) Mol. Pharmacol. 50, 728-735[Abstract]
22. Polyak, K., Xia, Y., Zweir, J., Kinzler, K., and Vogelstein, B. (1997) Nature 389, 300-305[CrossRef][Medline] [Order article via Infotrieve]
23. Qui, M. S., and Green, S. H. (1992) Neuron 9, 705-717[CrossRef][Medline] [Order article via Infotrieve]
24. Barnes, P. J., and Karin, M. (1997) N. Engl. J. Med. 336, 1066-1071[Free Full Text]
25. Westwick, J. K., Weitzel, C., Leffert, H. L., and Brenner, D. A. (1995) J. Clin. Invest. 95, 803-810
26. Bogoyevitch, M. A., Gillespie-Brown, J., Ketterman, A. J., Fuller, S. J., Ben-Levy, R., Ashworth, A., Marshall, C. J., and Sugden, P. H. (1996) Circ. Res. 79, 162-173[Abstract/Free Full Text]


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
Y. Jing, J. A. Dowdy, M. R. Van Scott, and J. S. Fedan
Hyperosmolarity-Induced Dilation and Epithelial Bioelectric Responses of Guinea Pig Trachea in Vitro: Role of Kinase Signaling
J. Pharmacol. Exp. Ther., July 1, 2008; 326(1): 186 - 195.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
A. Hernandez, G. Lopez-Lluch, J. A. Bernal, P. Navas, and J. A. Pintor-Toro
Dicoumarol down-regulates human PTTG1/Securin mRNA expression through inhibition of Hsp90
Mol. Cancer Ther., March 1, 2008; 7(3): 474 - 482.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
S.-O. Lee, Y.-C. Chang, K. Whang, C.-H. Kim, and I.-S. Lee
Role of NAD(P)H:quinone oxidoreductase 1 on tumor necrosis factor-{alpha}-induced migration of human vascular smooth muscle cells
Cardiovasc Res, November 1, 2007; 76(2): 331 - 339.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. Du, D. H. Daniels, C. Asbury, S. Venkataraman, J. Liu, D. R. Spitz, L. W. Oberley, and J. J. Cullen
Mitochondrial Production of Reactive Oxygen Species Mediate Dicumarol-induced Cytotoxicity in Cancer Cells
J. Biol. Chem., December 8, 2006; 281(49): 37416 - 37426.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
S. Chu and T. J. Ferro
Identification of a hydrogen peroxide-induced PP1-JNK1-Sp1 signaling pathway for gene regulation
Am J Physiol Lung Cell Mol Physiol, November 1, 2006; 291(5): L983 - L992.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
K. S. Ahn, G. Sethi, A. K. Jain, A. K. Jaiswal, and B. B. Aggarwal
Genetic Deletion of NAD(P)H:Quinone Oxidoreductase 1 Abrogates Activation of Nuclear Factor-{kappa}B, I{kappa}B{alpha} Kinase, c-Jun N-terminal Kinase, Akt, p38, and p44/42 Mitogen-activated Protein Kinases and Potentiates Apoptosis
J. Biol. Chem., July 21, 2006; 281(29): 19798 - 19808.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
D. L. Dehn, D. Siegel, K. S. Zafar, P. Reigan, E. Swann, C. J. Moody, and D. Ross
5-Methoxy-1,2-dimethyl-3-[(4-nitrophenoxy)methyl]indole-4,7-dione, a mechanism-based inhibitor of NAD(P)H:quinone oxidoreductase 1, exhibits activity against human pancreatic cancer in vitro and in vivo.
Mol. Cancer Ther., July 1, 2006; 5(7): 1702 - 1709.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
M. M. Mc Gee, L. M. Greene, S. Ledwidge, G. Campiani, V. Nacci, M. Lawler, D. C. Williams, and D. M. Zisterer
Selective Induction of Apoptosis by the Pyrrolo-1,5-benzoxazepine 7-[{Dimethylcarbamoyl}oxy]-6-(2-naphthyl)pyrrolo-[2,1-d] (1,5)-benzoxazepine (PBOX-6) in Leukemia Cells Occurs via the c-Jun NH2-Terminal Kinase-Dependent Phosphorylation and Inactivation of Bcl-2 and Bcl-XL
J. Pharmacol. Exp. Ther., September 1, 2004; 310(3): 1084 - 1095.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
K. Davison, K. K. Mann, S. Waxman, and W. H. Miller Jr
JNK activation is a mediator of arsenic trioxide-induced apoptosis in acute promyelocytic leukemia cells
Blood, May 1, 2004; 103(9): 3496 - 3502.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
R. A. Frost, G. J. Nystrom, and C. H. Lang
Lipopolysaccharide and proinflammatory cytokines stimulate interleukin-6 expression in C2C12 myoblasts: role of the Jun NH2-terminal kinase
Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2003; 285(5): R1153 - R1164.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
K. M. Dhandapani, M. Hadman, L. De Sevilla, M. F. Wade, V. B. Mahesh, and D. W. Brann
Astrocyte Protection of Neurons: ROLE OF TRANSFORMING GROWTH FACTOR-{beta} SIGNALING VIA A c-Jun-AP-1 PROTECTIVE PATHWAY
J. Biol. Chem., October 31, 2003; 278(44): 43329 - 43339.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
D. L. Dehn, D. Siegel, E. Swann, C. J. Moody, and D. Ross
Biochemical, Cytotoxic, and Genotoxic Effects of ES936, a Mechanism-Based Inhibitor of NAD(P)H:quinone Oxidoreductase 1, in Cellular Systems
Mol. Pharmacol., September 1, 2003; 64(3): 714 - 720.
[Abstract] [Full Text] [PDF]


Home page
CVIHome page
A. P. Kater, M. P. Peppelenbosch, D. P. M. Brandjes, and M. Lumbantobing
Dichotomal Effect of the Coumadin Derivative Warfarin on Inflammatory Signal Transduction
Clin. Vaccine Immunol., November 1, 2002; 9(6): 1396 - 1397.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M.-E. Janelle, A. Gravel, J. Gosselin, M. J. Tremblay, and L. Flamand
Activation of Monocyte Cyclooxygenase-2 Gene Expression by Human Herpesvirus 6. ROLE FOR CYCLIC AMP-RESPONSIVE ELEMENT-BINDING PROTEIN AND ACTIVATOR PROTEIN-1
J. Biol. Chem., August 16, 2002; 277(34): 30665 - 30674.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
C. Pipaon, P. Gutierrez, J. C. Montero, M. Lorenzo, A. Eguiraun, J. A. De la Fuente, A. Pandiella, J. Leon, and J. M. Ortiz
Mitogen-activated Protein Kinase Routes as Targets in the Action of Diaza-anthracene Compounds with a Potent Growth-inhibitory Effect on Cancer Cells
Mol. Cancer Ther., August 1, 2002; 1(10): 811 - 819.
[Abstract] [Full Text] [PDF]


Home page
JCBHome page
M. Ryten, P. M. Dunn, J. T. Neary, and G. Burnstock
ATP regulates the differentiation of mammalian skeletal muscle by activation of a P2X5 receptor on satellite cells
J. Cell Biol., July 22, 2002; 158(2): 345 - 355.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. M. Mc Gee, G. Campiani, A. Ramunno, V. Nacci, M. Lawler, D. C. Williams, and D. M. Zisterer
Activation of the c-Jun N-terminal Kinase (JNK) Signaling Pathway Is Essential during PBOX-6-induced Apoptosis in Chronic Myelogenous Leukemia (CML) Cells
J. Biol. Chem., May 17, 2002; 277(21): 18383 - 18389.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
O. LaRochelle, V. Gagne, J. Charron, J.-W. Soh, and C. Seguin
Phosphorylation Is Involved in the Activation of Metal-regulatory Transcription Factor 1 in Response to Metal Ions
J. Biol. Chem., November 2, 2001; 276(45): 41879 - 41888.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
T. Matsuguchi, T. Musikacharoen, T. R. Johnson, A. S. Kraft, and Y. Yoshikai
A Novel Mitogen-Activated Protein Kinase Phosphatase Is an Important Negative Regulator of Lipopolysaccharide-Mediated c-Jun N-Terminal Kinase Activation in Mouse Macrophage Cell Lines
Mol. Cell. Biol., October 15, 2001; 21(20): 6999 - 7009.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
D. Chakravortty, Y. Kato, T. Sugiyama, N. Koide, M. M. Mu, T. Yoshida, and T. Yokochi
Inhibition of Caspase 3 Abrogates Lipopolysaccharide-Induced Nitric Oxide Production by Preventing Activation of NF-{kappa}B and c-Jun NH2-Terminal Kinase/Stress-Activated Protein Kinase in RAW 264.7 Murine Macrophage Cells
Infect. Immun., March 1, 2001; 69(3): 1315 - 1321.
[Abstract] [Full Text] [PDF]


Home page<